XOMA-Logo-Final.png
XOMA Receives $5.5 Million Payment from Rezolute
February 13, 2019 07:00 ET | XOMA Corporation
EMERYVILLE, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has received a $5.5 million payment from Rezolute, Inc., related to the Companies’ 2017...
XOMA-Logo-Final.png
XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 07, 2018 16:05 ET | XOMA Corporation
Transformed business model to a royalty aggregator with extensive asset portfolio and capital;Added nine new partner-funded programs in 2017 with potential for milestone and royalty payments;Current...
XOMA-Logo-Final.png
XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.
December 07, 2017 08:35 ET | XOMA Corporation
Expands portfolio of partner-funded programs$240 million in potential milestone paymentsRoyalties ranging from the high single-digits to mid-teens on net salesBeyond XOMA 358, XOMA adds three...
REZOLUTE.jpg
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
December 07, 2017 08:30 ET | Rezolute, Inc.
LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of...
REZOLUTE.jpg
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
October 17, 2017 08:00 ET | AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant...
REZOLUTE.jpg
AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
October 09, 2017 08:00 ET | AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 09, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company specializing in the development of innovative drug...
REZOLUTE.jpg
AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
October 04, 2017 08:00 ET | AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 04, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“The Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing platform technologies to target significant unmet...
REZOLUTE.jpg
AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
August 07, 2017 08:00 ET | AntriaBio, Inc.
LOUISVILLE, Colo., Aug. 07, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio”) (OTCQB:ANTB) and ActiveSite Pharmaceuticals (“ActiveSite”) today announced that AntriaBio has exclusively licensed...
AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
July 25, 2017 08:00 ET | AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - July 25, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies...
AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
July 17, 2017 08:00 ET | AntriaBio, Inc.
LOUISVILLE, CO--(Marketwired - July 17, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of...